Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

Trial Profile

Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2016

At a glance

  • Drugs Sorafenib (Primary) ; Capecitabine
  • Indications Breast cancer; Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 23 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top